Physician profile
Ya Li Chen
NPI 1174572440
$16,190.22
in general payments reported to CMS, 2019-2025
20 companies · $963 in 2025
The $963 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $620 · 2021: $462 · 2022: $11K · 2023: $1,376 · 2024: $1,133 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,983 · Education: $274 · Consulting Fee: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,982.96 |
| Education | $273.98 |
| Consulting Fee | $215.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $11,222.30 | 2019-2025 | Tremfya, Simponi Aria, Erleada |
| Janssen Scientific Affairs, LLC | $1,137.38 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $955.56 | 2019-2025 | Benlysta, Nucala |
| Amgen INC. | $728.32 | 2023-2025 | Tavneos, Otezla |
| Astrazeneca Pharmaceuticals LP | $654.83 | 2020-2025 | Saphnelo |
| Pfizer INC. | $438.96 | 2020 | |
| Abbvie INC. | $351.05 | 2020-2025 | |
| Genentech, INC. | $115.00 | 2019 | |
| Genentech USA, INC. | $110.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $108.62 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.77 | 2024 | |
| Aurinia Pharma U.S., INC. | $97.21 | 2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $46.90 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $33.93 | 2019-2021 | |
| Becton, Dickinson and Company | $31.89 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $19.43 | 2021 | |
| Covis Pharma Gmbh | $14.65 | 2021 | |
| Uswm, LLC | $13.55 | 2021 | |
| Lilly USA, LLC | $12.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ya Li Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.